Clinical Trials Search | Clareo Health

Showing 1-3 of 3 trials

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

NCT07109869

This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.

Vulvovaginal CandidiasesVulvovaginal Candidiasis, GenitalVulvovaginal Candidiasis (VVC)

pH-D Feminine Health LLC400 participantsStarted Aug 2025

Mobile, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +24 more locations

COMPLETED

Epidemiological Study in Subjects With Vulvovaginal Candidiases

NCT03064789

Epidemiological study about the clinical and microbiological progress in subjects under treatment for a severe vulvovaginal candidiases episody

Vulvovaginal Candidiases

Dr. Santiago Palacios43 participantsStarted Dec 2016

Madrid, Spain

WITHDRAWNPhase 2

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

NCT03167957

This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).

Vulvovaginal CandidiasesYeast InfectionVulvovaginitis+2 more

Matinas BioPharma Nanotechnologies, Inc.Started Dec 2019

Detroit, Michigan, United States

Data from ClinicalTrials.govTerms

Filters

Filters

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

Epidemiological Study in Subjects With Vulvovaginal Candidiases

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

Epidemiological Study in Subjects With Vulvovaginal Candidiases

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis